Angiotensin Inhibitors May Improve Survival in Sunitinib-Treated Renal Cell Carcinoma

Share this content:
Concomitant use of angiotensin system inhibitors may improve survival in mRCC with sunitinib.
Concomitant use of angiotensin system inhibitors may improve survival in mRCC with sunitinib.

Concomitant use of angiotensin system inhibitors may significantly improve overall survival and progression-free survival in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib, a study published in the journal Annals of Oncology has shown.

For the study, researchers retrospectively analyzed data from all patients with mRCC who received sunitinib as first-line treatment at a single cancer institute in France between 2004 and 2013.

Researchers identified 213 patients with a median follow-up of 3.6 years. Of those, 134 were hypertensive and 105 used angiotension system inhibitors.

Results showed that hypertensive patients had a longer median overall survival (41.6 vs 16.4 months; P < 0.0001) and a longer median progression-free survival (12.9 vs 5.6 months; < 0.0001) compared with non-hypertensive patients.

RELATED: Adding More Dietary Lycopene May Help Protect Against Kidney Cancer

In addition, multivariate analysis showed that those who took angiotensin system inhibitors had significantly better overall survival (HR = 0.40; 95% CI: 0.24-0.66; P < 0.001) and progression-free survival (HR = 0.55; 95% CI: 0.35-0.86;P = 0.009) compared with non-users.

Researchers found no difference on outcome between patients who started taking angiotensin system inhibitors before initiating sunitinib and those started during sunitinib treatment.


  1. Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv147.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs